Probucol: A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia

Antone F. Salel, Robert Zelis, H. S. Sodhi, James Price, Dean T. Mason

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Type II hyperlipoproteinemia or hyperbetalipoproteinemia (B-HLP), a condition with considerable atherogenic potential, is one of the most difficult lipid disorders requiring treatment. Since this abnormality responds minimally to dietary therapy alone, supplemental drug therapy is usually essential. Although the available bile-sequestering resins are effective in B-HLP, these substances are unpalatable and constipating. Since lifelong drug therapy is necessary as an adjunct to diet in the treatment of B-HLP, the ideal drug should be both effective and well tolerated. Probucol, a new cholesterol-lowering drug in tablet form without serious adverse effects, was evaluated in a 12-wk double-blind crossover trial in 11 patients with B-HLP whose serum cholesterol levels were in excess of 275 mg/dl. Probucol, in a dosage of 500 mg twice daily, produced a 10% or greater reduction in serum cholesterol levels in all 11 patients. Serum cholesterol was lowered (p G 0.0l) from 353 to 291 mg/dl in the entire group receiving probucol. There was no significant change (p > 0.1) in serum cholesterol (352 ingldl) during placebo administration. There were no untoward drug effects during the study, and all patients maintained excellent compliance to the schedule of medication. results indicate that probucol possesses considerable cholesterol-lowering activity and may be a promising new nontoxic therapeutic agent in type II hyperlipoproteinemia.

Original languageEnglish (US)
Pages (from-to)690-694
Number of pages5
JournalClinical pharmacology and therapeutics
Issue number6
StatePublished - Dec 1976

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Probucol: A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia'. Together they form a unique fingerprint.

Cite this